12:03 PM EDT, 05/03/2024 (MT Newswires) -- Pharmala Biotech Holdings ( MDXXF ) -- a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA -- was at last look up near 8% around midday Friday after officially launching its Prescribers Portal for medical practitioners to use when teaching patients about MDMA, its effects, and the potential ability to access the molecule. The portal, is available only to pre-approved medical professionals, a statement said.

"With the upcoming review of MDMA for the treatment of PTSD by the US Food and Drug Administration, and with increasing insurance coverage in Canada for treatments based on psychedelic molecules, we believe it is important for medical practitioners to have access to high quality educational resources regarding MDMA, its effects, and its potential use for patients with Post-Traumatic Stress Disorder," said CEO Nicholas Kadysh. "As the research and regulatory environment regarding MDMA has moved quickly, most psychiatrists and medical practitioners are seeking information on clinical use and the regulatory pathways for MDMA access available in Canada."

The company added it is also working towards the creation of an accredited training and Continuing Education module for physicians in Canada and Australia, which summarizes technical information pertaining to the clinical use of MDMA.

Price: 0.21, Change: +0.02, Percent Change: +7.89